ArticleDiscover oncology2025
RAD51 modulates in nasopharyngeal carcinoma cells by regulating Caspase-8-mediated pyroptosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveRadiotherapy is a first-line treatment for nasopharyngeal carcinoma (NPC), but resistance to radiation remains a major clinical challenge. This study aimed to investigate the role of RAD51, a key homologous recombination repair protein, in radiotherapy resistance of NPC and to elucidate its underlying molecular mechanisms.
methodsRAD51 expression levels were examined in tumor and adjacent normal tissues from 20 NPC patients and in the radioresistant NPC cell line CNE2. Functional assays were conducted using recombinant RAD51 protein, the RAD51 inhibitor B02, and the Caspase-8 inhibitor Z-IETD-FMK. Changes in cell viability, lactate dehydrogenase (LDH) release, and expression of pyroptosis-related proteins were analyzed to assess the effects of RAD51 modulation.
resultsRAD51 expression was significantly elevated in NPC tumor tissues and CNE2 cells compared to normal controls (P < 0.05). Recombinant RAD51 protein enhanced CNE2 cell viability and inhibited Caspase-8-mediated pyroptosis pathways (P < 0.05). Inhibition of RAD51 by B02 reduced its expression and cell viability (P < 0.05), while the addition of Z-IETD-FMK further suppressed pyroptosis and promoted survival in RAD51-overexpressing cells (P < 0.05).
conclusionThis study is the first to demonstrate that RAD51 promotes radiotherapy resistance in NPC cells by suppressing Caspase-8-dependent pyroptosis. These findings suggest that targeting RAD51 may represent a novel strategy to overcome radioresistance and improve therapeutic outcomes in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.